Conference Coverage

A call to action on metabolic syndrome and pediatric psoriasis


 

EXPERT ANALYSIS FROM WCD 2015

References

In another small study, this by investigators at Tufts University, Boston, 6 of 20 children with psoriasis (30%) met criteria for the metabolic syndrome, compared with just 1 of 20 matched nonpsoriatic controls (Pediatr. Dermatol. 2013;30:700-5).

Dr. Paller said that if dermatologists and primary care physicians are to successfully collaborate in tackling the comorbid metabolic disorders associated with pediatric psoriasis, a prerequisite is that dermatologists are going to have to do a better job of educating their primary care colleagues about the skin disease as manifest in children.

“I think it’s very important that pediatricians are aware that psoriasis is a risk factor for metabolic syndrome. But pediatric psoriasis is often misdiagnosed by primary care physicians who mistake it for eczema or tinea infection or contact dermatitis,” according to the pediatric dermatologist.

In one eye-catching Australian study, she noted, a mere 9% of patients with pediatric psoriasis were correctly diagnosed before referral to a dermatologist (Australas. J. Dermatol. 2012;53:98-105).

Pediatric psoriasis: not just skin deep

In addition to the increased risk of metabolic disorders faced by pediatric psoriasis patients, other common comorbidities include depression, anxiety disorders, impaired self-esteem and quality of life, arthritis, and Crohn’s disease, Dr. Paller observed.

Quality of life. “The quality of life impact of psoriasis is profound. It’s a highly visible disorder, which affects the development of self-esteem and social relationships,” Dr. Paller said.

Investigators at Texas A&M University applied the Pediatric Quality of Life Inventory Version 4.0 to 208 patients aged 2-17 years with moderate to severe psoriasis and compared the results to published data on children with arthritis, asthma, diabetes, and psychiatric disorders. Health-related quality of life turned out to be more impaired in the psoriasis patients than in those with diabetes. The quality-of-life impairment associated with pediatric psoriasis was comparable to that of having asthma or arthritis, albeit not as severe as for pediatric psychiatric disorders (Eur. J. Pediatr. 2012;171:485-92).

Psychiatric disorders. A study of more than 7,400 pediatric psoriasis patients concluded they had an adjusted 25% increased risk of developing depression, compared with psoriasis-free controls, as well as a 32% increased risk of anxiety disorders and a 55% greater risk of bipolar disorder (J. Am. Acad. Dermatol. 2012;67:651-7.e2).

Psoriatic arthritis. An estimated 1 in 10 U.S. children with psoriasis report having arthritis, often classified as juvenile idiopathic arthritis (JAMA Dermatol. 2013;149:1180-5).

Crohn’s disease. A large German epidemiologic study concluded that psoriasis was associated with a 3.69-fold increased risk of Crohn’s disease. There was no increased risk of ulcerative colitis (Br. J. Dermatol. 2010;162:633-6).

Dr. Paller reported receiving research grants from Amgen and Leo and serving as a consultant to AbbVie.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

WCD: IL-23p19 inhibitors yield ‘promising’ psoriasis results
MDedge Dermatology
WCD: Secukinumab shows effectiveness for nail, palmoplantar psoriasis
MDedge Dermatology
Screening for Psoriatic Arthritis in Psoriasis Patients
MDedge Dermatology
EULAR’s psoriatic arthritis recommendations gain new drugs
MDedge Dermatology
Clinical Trial Update: Topical Therapy for Plaque Psoriasis
MDedge Dermatology
Guselkumab prevails in phase II psoriasis trial
MDedge Dermatology
WCD: Touch avoidance is a new dimension of psoriatic impairment
MDedge Dermatology
Novel Psoriasis Therapies and Patient Outcomes, Part 3: Systemic Medications
MDedge Dermatology
Undiagnosed Psoriatic Arthritis
MDedge Dermatology
Secukinumab proves successful against psoriatic arthritis in FUTURE 2 trial
MDedge Dermatology